Similar articles

• In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells.

  Kars MD, Işeri OD, Ural AU, Gündüz U. Kars MD, et al. Anticancer Res. 2007 Nov-Dec;27(6B):4031-7. Anticancer Res. 2007. PMID: 18225567
• Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.

  Clyburn RD, Reid P, Evans CA, Lefley DV, Holen I. Clyburn RD, et al. Cancer Chemother Pharmacol. 2010 Apr;65(5):969-78. doi: 10.1007/s00280-009-1106-6. Cancer Chemother Pharmacol. 2010. PMID: 19730863
• Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.

  Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Pinzòn-Daza ML, Giordano A, Desiderio V, Ghigo D, De Rosa G, Caraglia M, Riganti C. Kopecka J, et al. Oncotarget. 2016 Apr 12;7(15):20753-72. doi: 10.18632/oncotarget.8012. Oncotarget. 2016. PMID: 26980746 Free PMC article.
• Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.

  Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, Chung HY, Kim HS. Kim TH, et al. Biochim Biophys Acta. 2014 Jan;1840(1):615-25. doi: 10.1016/j.bbagen.2013.10.023. Epub 2013 Oct 24. Biochim Biophys Acta. 2014. PMID: 24161697
• Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.

  Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Ottewell PD, et al. Mol Cancer Ther. 2009 Oct;8(10):2821-32. doi: 10.1158/1535-7163.MCT-09-0462. Epub 2009 Sep 29. Mol Cancer Ther. 2009. PMID: 19789217